Remove Clinical Trials Remove Events Remove Topical Remove Treatment
article thumbnail

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Puff Puff Post

INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. With enrollment completed, treatment is expected to conclude towards the end of March and results are anticipated to be announced in the second half of calendar 2020.

article thumbnail

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Puff Puff Post

INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. With enrollment completed, treatment is expected to conclude towards the end of March and results are anticipated to be announced in the second half of calendar 2020.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Ketamine One Advances Research Capabilities via Controlled Substance Dealers Licence Application

Cannabis Law Report

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

article thumbnail

Cannabis laws in Japan: Is weed legal?

The Cannigma

In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes. CBD has become especially trendy in Tokyo, where CBD shops and cafes allow for the on-site consumption of CBD in edibles and topical treatments.

Law 137
article thumbnail

Chacruna Institute and Mexican grassroots organizations join forces in a Psilocybin Symposium to discuss the medicalization and commodification of psilocybin in the US

Cannabis Law Report

13, 2021 /PRNewswire-PRWeb/ — A host of scientific research and clinical trials around the world are affirming the remarkable effectiveness of psilocybin, the principal psychoactive component of “magic mushrooms,” in the treatment of a variety of medical conditions, including depression, anxiety, addiction, and PTSD.

article thumbnail

The John Hopkins Center for Psychedelic and Consciousness Research Publishes Inaugural Edition Of Newsletter

Cannabis Law Report

Future studies will explore psilocybin’s effectiveness as a new therapy for opioid addiction, Alzheimer’s disease, post-traumatic stress disorder (PTSD), post-treatment Lyme disease syndrome (formerly known as chronic Lyme disease), anorexia nervosa, and alcohol use in people with major depression. Upcoming Events.

Therapy 59
article thumbnail

Meredith Fisher-Corn, MD…….”Are You Able to Answer Your Patients’ Medical Marijuana Questions”

TheAnswerPage

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1). BMC Fam Pract.